Skip to main content

Day: October 20, 2025

Press Release: Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-dose

Sanofi’s high-dose influenza vaccine demonstrates superior protection for older adults against hospitalization vs standard-doseCompared to standard-dose influenza vaccines, Efluelda/Fluzone High-Dose demonstrated a reduction in laboratory-confirmed influenza hospitalizations by an additional 31.9% (95% CI, 19.7 to 42.2; p

Continue reading

2025 Q3 Sales: Revenue of €6.1 Billion, Stable on an Organic Basis. Strong Financial Discipline. 2025 Guidance Confirmed

NANTERRE (FRANCE) OCTOBER 20, 2025 THIRD-QUARTER 2025 SALES REVENUE OF €6.1 BILLION, STABLE ON AN ORGANIC BASIS STRONG FINANCIAL DISCIPLINE 2025 GUIDANCE CONFIRMEDSTABLE ORGANIC SALESReported sales down 3.7% due to a negative currency impact of €238m (-3.7%), Organic growth of 1.1% in product sales Solid growth in Electronics, Clean Mobility and Lifecycle Solutions China activity reflecting an unfavorable mix between Chinese customersSUSTAINED PROGRESS OF EFFICIENCY MEASURESEU-FORWARD European competitiveness plan at full-speed Launch of the global SIMPLIFY program to reduce indirect and structural costs Maximum flexibility in production cost managementSIGNIFICANT IMPROVEMENT IN DEBT PROFILE2026 maturities nearly repaid, with a balanced maturity profile from 2027 onwardCONFIRMED FULL-YEAR 2025 GUIDANCESales, operating...

Continue reading

Roche’s Tecentriq showed significant overall and disease-free survival benefits in bladder cancer with ctDNA-guided treatment

Tecentriq reduced the risk of death by 41% and the risk of disease recurrence or death by 36% compared with placebo1 IMvigor011 is the first global phase III study to read out pioneering a ctDNA- guided approach to post-surgery treatment in muscle-invasive bladder cancer Data being presented as part of the Presidential Symposium at the ESMO Congress 2025Basel, 20 October 2025 – Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the phase III IMvigor011 study evaluating Tecentriq® (atezolizumab) as an adjuvant treatment for people with muscle-invasive bladder cancer (MIBC) who are at risk of recurrence after surgery (cystectomy) and have detectable circulating tumour DNA (ctDNA). In this ctDNA-guided setting, Tecentriq reduced the risk of death (overall survival, OS) by 41% and the risk of disease recurrence...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.